Clay Siegall, president and CEO of Immunome, discusses what he saw investors getting excited for at the annual healthcare conference.
Clay Siegall
Advertisement
Articles by Clay Siegall
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline
2
Pediatricians Mostly Side With AAP Over CDC in Vaccine Guidance Debate: Report
3
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
4
Pharmaceutical Executive Daily: Mirum Pharmaceuticals Acquires Bluejay Therapeutics
5